enobosarm

Drug Overview

Enobosarm is an investigational medication that represents a new class of Targeted Therapy. It is designed to specifically interact with the body’s androgen receptors, which are proteins that respond to male hormones. Because it is highly selective, it is often called a “Smart Drug” or a Selective Androgen Receptor Modulator (SARM).

Unlike traditional steroids, which affect many different organs and can cause unwanted side effects, enobosarm is engineered to focus primarily on specific tissues like muscle, bone, and certain types of cancer cells. It is currently being studied for its ability to stop tumor growth and prevent the severe muscle loss that often occurs during cancer treatment.

• Generic Name: Enobosarm (also known as Ostarine, GTx-024, or MK-2866)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Selective Androgen Receptor Modulator (SARM)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Investigational. As of 2026, enobosarm has not yet received full FDA approval for commercial sale but has received “Fast Track” designation for specific breast cancer trials.

What Is It and How Does It Work? (Mechanism of Action)

Enobosarm works as a “molecular switch” that targets the Androgen Receptor (AR). In the human body, androgen receptors act like locks, and hormones act like keys. When the key turns the lock, it tells the cell to grow, repair, or divide.

At the molecular level, enobosarm is unique because of its tissue-selective nature:

1. Selective Binding: Enobosarm travels through the bloodstream and binds to the androgen receptor with high affinity. However, it changes the shape of the receptor in a way that is different from natural hormones or anabolic steroids.
2. Tissue-Specific Activation: In muscle and bone cells, it acts as an “agonist.” This means it turns the switch “ON,” triggering signaling pathways that increase protein synthesis and bone density. This helps patients stay strong during chemotherapy.
3. Cancer Growth Inhibition: In specific cancers, such as AR-positive/ER-positive breast cancer, enobosarm can act differently. It competes with other growth signals and can actually turn the growth switch “OFF” or stabilize it, preventing the cancer cells from multiplying.
4. Avoiding Off-Target Effects: Because of its chemical structure, it does not easily convert into estrogen or dihydrotestosterone (DHT). This helps avoid common side effects of hormonal therapy, such as hair loss, voice deepening in women, or prostate issues in men.

FDA Approved Clinical Indications

Currently, enobosarm is in the late stages of clinical testing. It does not have final FDA approval for general prescription use, but it is being investigated for the following:

Oncological uses (Investigational):

• AR-Positive, ER-Positive Metastatic Breast Cancer: For patients whose cancer has spread and has become resistant to standard hormone blockers.
• Cancer-Induced Cachexia: To treat severe weight and muscle loss in patients with lung or gastrointestinal cancers.

Non-oncological uses (Investigational):

• Stress Urinary Incontinence: To strengthen the pelvic floor muscles in women.
• Sarcopenia: Age-related muscle wasting.

Dosage and Administration Protocols

As an investigational drug, the exact dosage is determined by clinical trial protocols. It is usually taken once a day because it stays in the body for a long time.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Caution is required. Since the drug is processed by the liver, doctors usually lower the dose or monitor liver enzymes more frequently if the liver is not working perfectly.
• Renal (Kidney) Insufficiency: Current data suggests that dose adjustments for kidney issues may not be necessary, but close monitoring remains the standard of care.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 have provided significant data regarding the potential of enobosarm.

• Breast Cancer Results (ARTEST Trial): In Phase 2 studies for AR-positive metastatic breast cancer, enobosarm showed a Clinical Benefit Rate (CBR) of approximately 32% to 40% at 24 weeks. This means the cancer either shrank or stayed stable for at least six months in a significant number of patients.
• Muscle Preservation: In studies focused on cancer cachexia, patients taking 3 mg of enobosarm daily showed a measurable increase in lean body mass compared to those taking a placebo.
• Survival Impact: While final overall survival data for the 2026 period is still being analyzed, early results suggest that patients with higher androgen receptor expression in their tumors respond more favorably to the drug.

Safety Profile and Side Effects

Enobosarm is generally better tolerated than traditional hormone therapies or chemotherapy, but it does carry specific risks.

Black Box Warning:

None. (As an investigational drug, it has not yet been assigned a formal Black Box Warning by the FDA).

Common side effects (>10%)

• Liver Enzyme Elevation: Increases in ALT or AST levels (usually temporary).
• Nausea: Mild stomach upset shortly after taking the pill.
• Changes in Cholesterol: A slight decrease in “good” HDL cholesterol.
• Headache: Mild to moderate head pain.

Serious adverse events

• Hepatotoxicity: Rare but significant liver stress requiring treatment to stop.
• Hormonal Fluctuations: Potential changes in menstrual cycles in pre-menopausal women.

Management Strategies:

Doctors manage these side effects by performing regular blood tests. If liver enzymes rise too high, the medication is usually paused until levels return to normal.

Research Areas

Enobosarm is at the center of Regenerative Medicine research regarding “Muscle-Sparing Oncology.” Scientists are investigating how this drug can be used alongside Immunotherapy to keep the patient’s body strong enough to handle aggressive treatments. By stimulating the body’s natural muscle repair pathways, research aims to use enobosarm as a tool for physical recovery and long-term vitality in cancer survivors.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Liver Function Tests (LFTs): To ensure the liver is healthy enough to process the drug.
• Lipid Profile: To check baseline cholesterol levels.
• Tumor Biopsy: To confirm the cancer is “AR-positive” (has androgen receptors).

Precautions during treatment

• Liver Monitoring: Expect blood tests every 2–4 weeks during the first few months.
• Pregnancy: Enobosarm should not be used during pregnancy as it can interfere with fetal development.

“Do’s and Don’ts” list

• DO take the medication at the same time every day to maintain steady levels.
• DO report any yellowing of the skin or eyes (jaundice) to your doctor immediately.
• DON’T take over-the-counter supplements that claim to contain “Ostarine” or “SARMs,” as these are often unregulated and unsafe.
• DON’T stop the medication without consulting your oncology team, even if you feel better.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Enobosarm is an investigational drug and is not currently FDA-approved for the treatment of any condition. Patients should only access enobosarm through authorized clinical trials under the supervision of a licensed oncologist. Always seek the advice of your physician regarding any medical condition or treatment.